BRAF

Sep 08, 2017

CureMatch Co-Founders Study the Molecular Alterations of Genes to Develop Personalized Cancer Therapy Options

Aug 30, 2017

Array Biopharma To Present BEACON CRC Safety Lead-in And COLUMBUS Part 2 Results At European Society For Medical Oncology Congress (ESMO)

Jun 22, 2017

Novartis combination targeted therapy Tafinlar® + Mekinist® receives FDA approval for BRAF V600E mutant metastatic non-small cell lung cancer (NSCLC)

Jun 05, 2017

eFFECTOR Therapeutics Presents Phase 1 Data On eFT508, Its Lead Product Candidate, At ASCO 2017